FDA Rejects Myopia Drug Despite Successful Trial

Biotech firm Sydnexis faces obstacles in getting its eye drop treatment approved.

Mar. 13, 2026 at 9:39pm

Got story updates? Submit your updates here. ›

The FDA rejected Sydnexis's atropine eye drop treatment for pediatric myopia, even though the company's three-year trial met the key benchmarks the agency had previously set. The FDA claimed the benefits were not "clinically meaningful" because some children would still need glasses, despite the treatment reducing nearsightedness progression by about a third and preventing more severe myopia that can lead to other eye diseases later in life.

Why it matters

Myopia rates have soared in recent years, especially with increased screen time among children. Effective treatments that can slow the progression of nearsightedness could have significant public health benefits by reducing the risk of more serious eye conditions down the line. However, the FDA's decision-making process has come under scrutiny, raising concerns about how the agency evaluates and approves new drugs.

The details

Sydnexis has spent a decade developing atropine eye drops to treat pediatric myopia. The company's three-year randomized controlled trial succeeded on the key benchmarks the FDA had set years earlier, reducing myopia progression by about a third among children under 12 and more among the fastest progressors. Yet the FDA rejected Sydnexis's drug last October because the agency deemed the benefits were not "clinically meaningful" since some children would still need glasses.

  • Sydnexis has spent a decade developing the atropine eye drop treatment.
  • The company's three-year randomized controlled trial was completed recently.
  • The FDA rejected Sydnexis's drug application in October 2026.

The players

Marty Makary

The Food and Drug Administration Commissioner.

Vinay Prasad

The FDA's biologics chief who will be stepping down at the end of next month.

Sydnexis

The biotech firm that developed the atropine eye drop treatment for pediatric myopia.

Got photos? Submit your photos here. ›

What they’re saying

“Hallelujah. We hope the agency will stop torpedoing promising drugs, but the story of biotech firm Sydnexis's battle with the bureaucracy suggests more obstacles ahead.”

— The Editorial Board (The Wall Street Journal)

What’s next

The FDA's decision on Sydnexis's drug application has raised concerns about the agency's evaluation process for new treatments. It remains to be seen if the upcoming leadership change at the FDA's biologics division will lead to a more flexible and patient-centric approach to drug approvals.

The takeaway

The FDA's rejection of Sydnexis's effective myopia treatment, despite meeting the agency's own trial benchmarks, highlights the challenges innovative drug developers face in navigating the complex regulatory landscape. This case underscores the need for a more transparent and flexible FDA approval process that prioritizes public health benefits over narrow definitions of "clinical meaningfulness".